Biotest GmbH KGaA (LTS:0N6Z) Construction In Progress: £0.00 Mil (As of . 20)


What is Biotest GmbH KGaA Construction In Progress?

Biotest GmbH KGaA LTS:0N6Z Construction In Progress is £0.00 Mil as of . 20.

Biotest GmbH KGaA Construction In Progress Historical Data

* Premium members only.

The historical data trend for Biotest GmbH KGaA's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biotest GmbH KGaA Construction In Progress Chart

Biotest GmbH KGaA Annual Data
Trend
Construction In Progress

Biotest GmbH KGaA Semi-Annual Data
Construction In Progress

Biotest GmbH KGaA Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

What does a Construction In Progress of £0.00 Mil mean?
Biotest GmbH KGaA (LTS:0N6Z) has a Construction In Progress of £0.00 Mil as of . 20. Construction in Progress records the amount of construction work that is not complete. View historical data on Biotest GmbH KGaA and its competitors.
Is Biotest GmbH KGaA's Construction In Progress too high?
Biotest GmbH KGaA's current Construction In Progress is £0.00 Mil.
How does Biotest GmbH KGaA's Construction In Progress compare to ?
Biotest GmbH KGaA's Construction In Progress of £0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Construction In Progress for a Biotechnology company?
A good Construction In Progress depends on the Biotechnology industry context. However, Construction In Progress should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Construction In Progress mean?
A high Construction In Progress can signal that a stock is expensive relative to its fundamentals. Construction in Progress records the amount of construction work that is not complete. View historical data on Biotest GmbH KGaA and its competitors. Biotest GmbH KGaA's current Construction In Progress is £0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biotest GmbH KGaA stock overvalued right now?
Biotest GmbH KGaA (LTS:0N6Z) has a current Construction In Progress of £0.00 Mil. The current Construction In Progress is £0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Construction In Progress calculated?
Construction In Progress is calculated from a company's financial statements. For Biotest GmbH KGaA (LTS:0N6Z), the current Construction In Progress is £0.00 Mil as of . 20. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Biotest GmbH KGaA Business Description

Comparable Companies
Biotest GmbH & Co KGaA is a specialist in haematology, clinical immunology, and intensive care medicine. The group develops, manufactures, and markets plasma proteins and biotherapeutic drugs. The group's value chain extends from pre-clinical and clinical development to world-wide marketing and distribution. It manufactures immunoglobulins, clotting factors, and albumins, which are derived from human blood plasma. The group markets its products in Europe, the Middle East, China, Australia, Africa, and the USA.